Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced TP53 mutant gastroesophageal cancer

The Oncologist(2025)10.1093/oncolo/oyaf400Source: DataRank Database

NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced TP53 mutant gastroesophageal cancer is a research paper published in The Oncologist (2025). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access0 citations

Download PDF

Cite:

Linked data & code

nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT03641313

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 0.00)OA: goldTopics (45)IDs (PubMed, PMC, OpenAlex)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (17)

Shannon Stockton ORCID,Heloisa P. Soares ORCID,Farshid Dayyani ORCID,Anwaar Saeed ORCID,Edward Kim ORCID

Live enrichment

PubMed:41335461 PMC:PMC12718112 OpenAlex:https://openalex.org/W4416957858

National Institutes of Health

Grant: UM1CA186689

National Institutes of Health

Grant: P30CA068485

National Institutes of Health

Grant: HHSN261200800001E

NCI NIH HHS

Grant: UM1 CA186717

CCR NIH HHS

Grant: HHSN261200800001C

NCI NIH HHS

Grant: P30 CA093373

NCI NIH HHS

Grant: UM1 CA186690

FWCI

0.00

Citation Percentile

0.4%

goldLicense: cc-by

journalhttps://academic.oup.com/oncolo/advance-article-pdf/doi/10.1093/oncolo/oyaf400/65728435/oyaf400.pdf

publisherhttps://academic.oup.com/oncolo/advance-article-pdf/doi/10.1093/oncolo/oyaf400/65728435/oyaf400.pdf

publisherhttps://academic.oup.com/oncolo/article-pdf/30/12/oyaf400/65728435/oyaf400.pdf

journalhttps://doi.org/10.1093/oncolo/oyaf400

repositoryhttps://pubmed.ncbi.nlm.nih.gov/41335461

Fields of Study

Cancer-related Molecular PathwaysNF-κB Signaling PathwaysPancreatic and Hepatic Oncology ResearchMedicineHumansIrinotecanMaleFemaleMiddle AgedAntineoplastic Combined Chemotherapy ProtocolsAgedEsophageal NeoplasmsStomach NeoplasmsTumor Suppressor Protein p53MutationAdultPyrazolesAdenocarcinomaIsoxazolesPyrazines

MeSH Terms

IrinotecanAdenocarcinomaAdultAgedAntineoplastic Combined Chemotherapy ProtocolsEsophageal NeoplasmsFemaleHumansIsoxazolesMaleMiddle AgedMutationPyrazinesPyrazolesStomach NeoplasmsTumor Suppressor Protein p53

Keywords

IrinotecanRegimenCancerAdverse effectPhases of clinical researchDNA damage repairGastroesophageal CancerTp53 MutationAtr Inhibition

NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced TP53 mutant gastroesophageal cancer

FAIR Checklist

Authors (17)

Funding (7 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)